王峰，女，主治醫(yī)師，博士，中山大學(xué)腫瘤防治中心青年人才(2014年)，自費(fèi)留學(xué)生獎(jiǎng)學(xué)金 (2011年)，UT MD Anderson 腫瘤中心Rosalie B. Hite 獎(jiǎng)學(xué)金 (2010年-2012年)，德州大學(xué)生物醫(yī)學(xué)研究生院Student Travel Award (2010年, 2012年)，德州大學(xué)生物醫(yī)學(xué)研究生院 全額獎(jiǎng)學(xué)金 (2008年-2009年)，廣東省研究生畢業(yè)論文 (2009)。自然科學(xué)基金委青年科學(xué)基金活性氧/kB 信號(hào)通路在腦膠質(zhì)瘤干細(xì)胞分化中的作用及其調(diào)控機(jī)制 2014年1月-2016年12月 負(fù)責(zé)人教育部高等學(xué)校博士學(xué)科點(diǎn)專項(xiàng)科研基金 腦膠質(zhì)瘤干細(xì)胞活性氧調(diào)控kB通路對(duì)分化的影響及其作用機(jī)制2014年1月-2016年1月 負(fù)責(zé)人自然科學(xué)基金面上項(xiàng)目microRNA-214在結(jié)直腸癌肝轉(zhuǎn)移中的作用及機(jī)制研究2014年1月-2016年12月 主要研究者自然科學(xué)基金委青年科學(xué)基金 新型糖酵解控制劑3-BrOP逆轉(zhuǎn)胃腸腫瘤細(xì)胞多藥耐藥性的作用及其機(jī)制 2014年1月-2016年12月主要研究者M(jìn)D Anderson腫瘤中心姐妹醫(yī)院合作基金 2014年1月-2015年12月主要研究者發(fā)表學(xué)術(shù)論文　　1. Wang F, Wang FH, Bai L, Xu RH. Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. Onco Targets Ther. 2014;7:501-511.　　2. Chen WW, Wang F, Chen S, Wang L, Ren C, Luo HY, Wang FH, Li YH, Zhang DS, Xu RH. Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma. Ann Thorac Surg. 2014 Apr 11. pii: S0003-4975(14)00373-7 (co-first author).　　3. Chen WW, Wang F, Zhang DS, Luo HY, Wang ZQ, Wang FH, Qiu MZ, Ren C, Wei XL, Wu WJ, Li YH, Xu RH. Primary small cell carcinoma of the esophagus: clinicopathological study of 44 cases. BMC Cancer. 2014;14:222. (co-first author)　　4. Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH, Xu RH. Identification of miR-214 as a negative regulator of colorectal cancer liver metastasis via regulation of FGFR1 expression. Hepatology. 2014 Mar 11. doi: 10.　　5. He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol. 2014;20(1):264-73. (co-first author).　　6. He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Jin Y, Wei XL, Xu RH. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer. PLoS One. 2013;8(12):e83921. (co-first author).　　7. He MM, Wu WJ, Wang F, Wang ZQ, Zhang DS, Luo HY, Qiu MZ, Wang FH, Ren C, Zeng ZL, Xu RH. S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis. PLoS One. 2013;8(12):e82798. (co-first author).　　8. Chen DL, Wang ZQ, Ren C, Zeng ZL, Wang DS, Luo HY, Wang F, Qiu MZ, Bai L, Zhang DS, Wang FH, Li YH, Xu RH. Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. J Transl Med. 2013;11(1):277.　　9. Wei XL, Qiu MZ, Chen WW, Jin Y, Ren C, Wang F, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J Transl Med. 2013;11:249. doi: 10.1186/1479-5876-11-249.　　10. Chen WW, Wang F, Xu RH. Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-ysis. PLoS One. 2013;8(7):e68974. (co-first author).　　11. Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, Keating MJ, Huang P. Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53-/- mouse model and primary human leukemia cells. Leukemia. 2014;28(1):118-28.　　12. Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F, Li YH, Xu RH. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013;71(4):1065-72.　　13. Wu WJ, Hu KS, Chen DL, Zeng ZL, Luo HY, Wang F, Wang DS, Wang ZQ, He F, Xu RH. Prognostic relevance of BRD7 expression in colorectal carcinoma. Eur J Clin Invest. 2013;43(2):131-40.　　14. Yuan SQ, Wang F, Wang L, Chen G, Zhang H, Feng L, Colman H, Keating MJ, Xu RH, Wang JP, Huang P. Low mitochondrial respiration and high glycolytic metabolism in glioblastoma stem cells: a biochemical basis for new therapeutic strategies. Stem Cells. 2013 ;31(1):23-34. (co-first author).　　15. Wang F, Yuan SQ, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, Rao HL, Xia Y, Jiang WQ, Huang HQ, Xia ZJ, Sun XF, Xu RH. High hepatits B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev. 2012; 21(3):261-7.　　16. Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating M, Liu J, McKeehan W, Wang HM, Luo Y, Huang P. Novel Role of NOX in Supporting Aerobic Glycolysis in Cancer Cells with Mitochondrial Dysfunction and as a Potential Target for Cancer Therapy. PLoS Biol. In press.　　17. Li ZH, Qiu MZ, Zeng ZL, Luo HY, Wu WJ, Wang F, Wang ZQ, Zhang DS, Li YH, Xu RH. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC). J Transl Med. 2012; 10(1):21.　　18. Chen G, Wang F, Trachootham D, Huang P. Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds. Mitochondrion. 2010; 10 (6): 614-25.　　19. Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, Qiu MZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol Rep. 2010; 23(6): 1735-45.　　20. Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, Zhou ZW, Chen XQ. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy. 2010;56(2):94-100.　　21. Wang F, Ogasawara MA, Huang P. Small mitochondria-targeting molecules as anti-cancer agents. Mol Aspects Med. 2010; 31(1):75-92.　　22. Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, Ajani JA, Huang P. Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal.2009; 11(5):1083-1095.　　23. Li FH, Chen XQ, Luo HY, Li YH, Wang F, Qiu MZ, Teng KY, Li ZH, Xu RH. Prognosis of 84 intrahepatic cholangiocarcinoma patients. Chinese journal of Cancer.2009;28(5):528-532.　　24. Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic ysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer. 2008; 8:115.　　25. Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ.A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer. Chemotherapy.2008; 54(3):228-235.　　26. Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, Lin TY, Huang HQ, Xia ZJ, Guan ZZ. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer, 2007;109:1360-1364.　　27. Shi YX, Xu RH, Jiang WQ, Zhang L, Lin TY, Li YH, Xia ZJ, Luo HY, Han B, Wang F, He YJ, Guan ZZ. Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer. Ai Zheng. 2007; 26(12):1381-4.　　28. Luo HY, Li YH, Zhang L, Jiang WQ, Shi YX, Wang F, He YJ, Xu RH. Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer. Ai Zheng.1007; 26:905-908.　　29. Qiu MZ, Xu F, Wang SS, Luo HY, Wang F, Li FH, Sun XF, Xu GC, Lin TY, Huang HQ, Jiang WQ, Guan ZZ, Xu RH. Responses of 109 soft tissue sarcoma patients to chemotherapy. Ai Zheng. 2007; 26(12):1344-1349.　　30. Han B, Xu RH, Shi YX, Li YH, Luo HY, Wang F, Hou JH, Cai MY, Jiang WQ. Expression and clinical significance of hypoxia-inducible factor-1alpha in gastric cancer. Ai Zheng. 2006; 25:1439-1442.國(guó)際會(huì)議摘要　　1. Wang F, Chen WW, Chen SB. Detailed Prognostic Factors Analysis Of Primary Esophageal Small Cell Carcinoma: A Chinese Multicenter Study With 211 Patients. Global Academic Programs 2014 Conference.　　2. Wang F, Yuan SQ, Chen G, Kim S, Yang J, Feng L, Lee JS, Li XN, Xu RH, Huang P. Role of mitochondrial ROS in activation of glioma stem cells and promotion of cancer development. 105屆美國(guó)腫瘤研究協(xié)會(huì)年會(huì), 2014.　　3. Wang F, Yuan SQ, Chen G, Kim S, Hammodi N, Feng L, Lu WQ, Lee JS, and Huang P. Potential Role of Reactive Oxygen Species in Mediating Glioblastoma Stem Cell Differentiation. 103屆美國(guó)腫瘤研究協(xié)會(huì)年會(huì)(大會(huì)發(fā)言)，2012. Cancer Res, 2012; 72(8 Supplement): 999.　　4. Wang F, Hammodi N, Yuan SQ, Chen G, Feng L, Kim S, Colman H, Lee JS, Xu RH, and Huang P. Potential role of reactive oxygen species in affecting tumorigenicity of glioblastoma stem cells. 101屆美國(guó)腫瘤研究協(xié)會(huì)年會(huì)，2010.所獲榮譽(yù)和**• 中山大學(xué)腫瘤防治中心青年人才(2014年).• 自費(fèi)留學(xué)生獎(jiǎng)學(xué)金 (2011年).• UT MD Anderson 腫瘤中心Rosalie B. Hite 獎(jiǎng)學(xué)金 (2010年-2012年).• 德州大學(xué)生物醫(yī)學(xué)研究生院Student Travel Award (2010年, 2012年).• 德州大學(xué)生物醫(yī)學(xué)研究生院 全額獎(jiǎng)學(xué)金 (2008年-2009年).• 廣東省研究生畢業(yè)論文 (2009).• 中山大學(xué)柯麟獎(jiǎng)學(xué)金 (2007).• 中山大學(xué)學(xué)生干部 (2006).